Gastroenterology
Sam Costello (The Queen Elizabeth Hospital in Adelaide) presented recent evidences about FMT and IBDs.
The findings of a recent study suggest that phages can be used to treat IBD and other diseases associated with gut microbes.
The findings of a recent study suggest that engineered native gut bacteria could be employed to help treat certain diseases such as diabetes.
A recent study suggests that the microbiome changes in response to human consumption of non-nutritive sweetener may induce glycemic changes in consumers in a personalized manner.
The findings of a new research suggest that different responses to statins can be explained by the variation in the human microbiota.
The findings of a new research illuminate the link between IBS and gut bacteria, and suggest that histamine is a good target for therapies against the condition.
Maria Teresa Abreu (University of Miami, USA) discussed some new strategies to design clinical trials.
Theresa Pizarro, (Case Western Reserve University School of Medicine) discussed the roles of epithelial barrier’s cytokines, gut microbiome and Gasdermin in IBD patients.
Probiotic supplements with ethanol-metabolizing activity may help reduce the disease burden of excessive alcohol consumption.
Sudarshen Paramsothy (University of New South Wales, Australia) discussed the controversials about FMT in IBD patients.
